AzTrials
AzTrials

Melanoma (Skin)Phase 1NCT00022568

Vaccine Therapy in Treating Patients With Metastatic Melanoma

A Phase 1 study testing recombinant vaccinia-TRICOM vaccine in people with Melanoma (Skin), run by Herbert Irving Comprehensive Cancer Center at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Melanoma (Skin)
What is being tested?
recombinant vaccinia-TRICOM vaccine
Type of treatment
Vaccines
How many people
Not given
Where
1 siteUnited States
Study dates
Aug 2001to not given
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

DISEASE CHARACTERISTICS:

  • Histologically confirmed metastatic non-resectable cutaneous, subcutaneous, or lymph node malignant melanoma
  • Lesion(s) must be accessible to percutaneous injection
  • Measurable lesion(s)
  • At least 1.0 cm
  • Previously treated brain metastases with no evidence of disease or edema on MRI or CT scan allowed
  • At least 6 weeks since prior definitive therapy (surgery or radiotherapy)
  • No untreated or edematous metastatic brain lesions or leptomeningeal disease
  • No ascites or pleural effusions

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Performance status:

  • ECOG 0-1

Life expectancy:

  • More than 3 months

Hematopoietic:

  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3
  • Absolute granulocyte count at least 3,000/mm3
  • Hemoglobin at least 10 g/dL

Hepatic:

  • Direct bilirubin no greater than 1.5 mg/dL
  • Transaminases no greater than 2 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2 times ULN
  • No severe coagulation disorder with PT/PTT greater than 2 times normal (without anticoagulation medications)
  • No hepatic insufficiency
  • No alcoholic cirrhosis

Renal:

  • Creatinine no greater than 2.0 mg/dL OR
  • Creatinine clearance at least 60 mL/min
  • No renal insufficiency

Cardiovascular:

  • No congestive heart failure
  • No serious cardiac arrhythmias
  • No evidence of recent prior myocardial infarction on EKG
  • No clinical coronary artery disease

Pulmonary:

  • No chronic obstructive pulmonary disease

Immunologic:

  • No prior eczema
  • HIV negative
  • No immunocompromising conditions, (e.g., active autoimmune disease, leukemia, lymphoma, skin diseases, or open wounds)
  • No clinical or laboratory evidence of an underlying immunosuppressive disorder
  • No active or chronic infections
  • No significant allergy or hypersensitivity to eggs

Other:

  • No active seizure disorders
  • No other malignancy within the past 2 years except stage I cervical cancer or basal cell skin cancer, provided the tumor has been successfully treated and patient is currently disease free
  • No evidence of bone marrow toxicity
  • No other concurrent medical illness that would preclude study
  • No other contraindications to vaccinia virus administration
  • No encephalitis
  • Must be able to avoid close contact with children under 3 years of age; pregnant women; individuals with prior or active eczema or other open skin conditions; or immunosuppressed individuals for 7-10 days after each vaccination
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Prior vaccinia immunization required (e.g., smallpox vaccination)
  • More than 8 weeks since prior immunotherapy and recovered
  • No prior therapy with live vaccinia virus vector

Chemotherapy:

  • More than 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

  • At least 4 weeks since prior systemic corticosteroids
  • No concurrent systemic corticosteroids
  • No concurrent steroids

Radiotherapy:

  • See Disease Characteristics
  • More than 2 weeks since prior radiotherapy and recovered

Surgery:

  • See Disease Characteristics
  • More than 4 weeks since prior surgery for primary tumor or metastatic lesions and recovered

Other:

  • No concurrent immunosuppressive drugs

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Herbert Irving Comprehensive Cancer Center at Columbia University

    New York, New York, 10032

Other trials in United States

About this study

Official title: A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.

Read the detailed description

OBJECTIVES:

  • Determine the maximum tolerated dose of recombinant vaccinia-TRICOM vaccine in patients with metastatic melanoma.
  • Determine the clinical toxic effects of this vaccine in these patients.
  • Determine the safety of this vaccine in these patients.
  • Determine the clinical response of these patients to this vaccine.
  • Determine evidence of host anti-melanoma immune reactivity in these patients after treatment with this vaccine.

OUTLINE: This is a dose-escalation study.

Patients receive recombinant vaccinia-TRICOM vaccine once every 4 weeks for a total of 3 vaccinations. Patients with stable or responding disease may receive an additional course of vaccinations.

Cohorts of 3-6 patients receive escalating doses of recombinant vaccinia-TRICOM vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Quality of life is assessed at baseline, at each vaccine administration, and at study completion.

Patients are followed at 3 months.

PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study within 6-12 months.

Conditions
Melanoma (Skin)
Being tested
recombinant vaccinia-TRICOM vaccine
Keywords
stage IV melanoma, recurrent melanoma
Medical subject headings
Melanoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • recombinant vaccinia-TRICOM vaccineBiological

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2003 (estimated)
  2. Study startAug 2001

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
IDs, dates and publications
ClinicalTrials.gov ID
NCT00022568
Sponsor's protocol ID
CDR0000068831
Other IDs
CPMC-IRB-14387, AECM-01-003, NCI-3353
Status last verified
Dec 2003
First submitted
10 Aug 2001
Last updated
18 Dec 2013
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing recombinant vaccinia-TRICOM vaccine in people with Melanoma (Skin), run by Herbert Irving Comprehensive Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Dec 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in